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Although it has been suggested that older patients with classic osteoporotic fractures can be empirically treated for osteoporosis without testing bone mineral density, such testing remains necessary. Almost all randomized trials for the treatment of osteoporosis include only those patients with low bone density or low bone density and fractures. [1] [2] [3] In addition, bone mineral density testing can be used to establish a baseline or to monitor the response and adherence to treatment. Furthermore, 20%-30% of older patients with fractures have normal bone mineral density and do not require years of preventive medications. 2 All older patients with fractures should be advised to take adequate amounts of calcium and vitamin D each day, via supplement and/or diet, and be asked about osteoporosis risk factors and repeated injurious falls. 1 If a patient has low bone mass (e.g., T-score < -1.0 to -1.5 at any site), they should be offered treatment with bisphosphonate drugs.
2,3 Systematic reviews of bisphosphonate drugs suggest a relative reduction in fracture of about 50% compared with placebo, as well as a small reduction in all-cause mortality.
3 When bisphosphonate drugs are contraindicated (e.g., patients with esophagitis, recent dental implants or chronic kidney disease) or not tolerated (e.g., patients with refractory nausea or dyspepsia), several other evidence-based options exist. 1 Secondary prevention among older patients who present with a fragility fracture is evidencebased and fairly straightforward. Thus, it should be associated with a very high quality of care. However, systematic reviews of studies from many countries suggest rates of bone mineral density testing or treatment for osteoporosis of less than 10%-20% in the 6-12 months postfracture. 1 Thus, there remain many barriers to delivering optimal postfracture care (Appendix 1, available at www .cmaj .ca /lookup /suppl /doi :10 .1503 /cmaj.111999/-/DC1). These barriers exist at multiple levels, whether they reflect a disconnect between health care professionals delivering acute care and those responsible for ongoing preventive care, a lack of time on the part of the physician or a lack of knowledge on the part of the patient. 4 Indeed, the literature reports many studies on gaps and barriers to optimal care for osteoporosis; perhaps, rather than attempting to more precisely describe the problems and catalogue every reason for their existence, it is time we solve them.
Thus, the study by Leslie and colleagues is a welcome addition to the shallow pool of evidence we have for accelerating osteoporosis knowledge translation and improving the quality of postfracture care. 5 Patients were randomized to one of three groups. Patients in group 1 received usual care, patients in group 2 had mailed notification of the fracture sent to their physicians, and group 3 had notifications sent to both physicians and patients. The outcomes of the trial were not fractures, but process-of-care measures: the start of treatment for osteoporosis, bone mineral density testing and the composite of testing or treatment within 12 months of the fracture. Such quality indicators have been widely en dorsed and, when coupled with achievable benchmarks, are suitable for audit and feedback or pay-for-performance. 6 Moreover, when process-of-care measures are evidence-based and tightly linked to clinical events, they are sensitive measures of quality and are associated with better outcomes. 6 This trial is noteworthy because neither physicians nor patients provided informed consent and because both eligibility and outcomes were determined using routinely collected data housed in provincial databases. The province's ministry of health randomized the participants and concealed their allocation from researchers. This is exactly the type of quality-improvement research that fulfills the criteria for waiving informed consent (i.e., low-risk intervention, all treatments available outside the trial, patient identity concealed, outcomes derived from routinely collected data); 7 the researchers and Manitoba Health are to be lauded for their forward -thinking partnership efforts. In many other jurisdictions, this trial would have automatically required informed consent from both patients and physicians. Ironically, it is entirely permissible for physicians or policymakers to introduce any intervention desired in an uncontrolled fashion without consent and simply assume better outcomes.
Three important results can be highlighted from this trial. First, even in 2010, usual care is disconcertingly suboptimal (3.9% of patients in this group received bone mineral density testing, and 10.6% of patients received pharmacologic treatment for osteoporosis). 5 Second, the combination of physician and patient notification postfracture did not improve outcomes any more than notifying the physician alone. 5 Third, compared with usual care, the combined in ter ventions led to an absolute increase of 13.4% over usual care for bone mineral density testing and 14.9% for the composite end point at a cost of about four or five dollars per patient. 5 Is a modest improvement in the quality of care worth this amount of effort and research? A meta-analysis of eight trials of postfracture interventions showed a pooled increase of 36% (95% confidence interval [CI] 21-50) in bone mineral density testing and 20% (95% CI 10-30) in treatment for osteoporosis, but most of the interventions tested were more complex, expensive and difficult to implement than the interventions reported by Leslie and colleagues. 8 For example, the use of fracture liaison services or case managers in randomized trials has led to rates of almost 80% for bone mineral density testing and 50% for treatment. 8 In uncontrolled studies, rates of testing or treatment approach 90%-95%. 4 Although the interventions tested by Leslie and colleagues showed improvement over usual care, most of the patients were still not tested or did not receive treatment for osteoporosis. The investigators' a priori minimal important difference was only a 10% improvement, an arbitrary but common value in the literature. 5 Ideally, the minimal important difference should be determined before a trial using more validated and transparent methods. For example, osteoporosis experts have previously suggested a 20% improvement as their minimal important difference, 2 whereas researchers posited smaller improvements as being worthwhile when interventions are evidence-based, low-risk and low-cost.
Leslie and coworkers have developed and tested an effective, pragmatic, scalable, low-risk and inexpensive intervention for patients scattered over large geographic areas. Although the effects are modest, they are clinically worthwhile. Their interventions could be easily adopted elsewhere; not only should they be the new usual care in Manitoba, they should set the standard for control arms of future studies of quality improvement in osteoporosis.
